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Abstract: We recently demonstrated that Niemann-Pick C1 (NPC1), a ubiquitous 13-pass 
cellular membrane protein involved in lysosomal cholesterol transport, is a critical entry 
receptor for filoviruses. Here we show that Niemann-Pick C1-like1 (NPC1L1), an NPC1 
paralog and hepatitis C virus entry factor, lacks filovirus receptor activity. We exploited 
the structural similarity between NPC1 and NPC1L1 to construct and analyze a panel of 
chimeras in which NPC1L1 sequences were replaced with cognate sequences from NPC1. 
Only one chimera, NPC1L1 containing the second luminal domain (C) of NPC1 in place of 
its own, bound to the viral glycoprotein, GP. This engineered protein mediated authentic 
filovirus infection nearly as well as wild-type NPC1, and more efficiently than did a 
minimal NPC1 domain C-based receptor recently described by us. A reciprocal chimera, 
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NPC1 containing NPC1L1’s domain C, was completely inactive. Remarkably, an intra-
domain NPC1L1-NPC1 chimera bearing only a ~130-amino acid N–terminal region of 
NPC1 domain C could confer substantial viral  receptor activity on NPC1L1. Taken 
together, these findings account for the failure of NPC1L1 to serve as a filovirus receptor, 
highlight the central role of the luminal domain C of NPC1 in filovirus entry, and reveal 
the direct involvement of N–terminal  domain C sequences in NPC1’s function as a 
filovirus receptor. 
Keywords: Ebola virus; Marburg virus; filovirus; viral entry; Niemann-Pick C1; NPC1; 
Niemann-Pick C1-like1; NPC1L1; host factor; viral receptor 
 
1. Introduction 
Ebola virus (EBOV) and Marburg virus (MARV) are associated with fulminant and highly lethal 
outbreaks of hemorrhagic fever for which no approved vaccines or treatments exist. These viruses are 
members of the family Filoviridae  of enveloped viruses with nonsegmented negative-strand RNA 
genomes (filoviruses) [1]. Filoviruses encode a single entry glycoprotein, GP, which forms trimeric 
spikes at the viral surface [2,3]. The GP precursor is post-translationally cleaved by the pro-protein 
convertase furin within the Golgi compartment of virus-producer cells, yielding two subunits, GP1 and 
GP2. GP1 binds to cellular receptors and controls GP2 conformation; GP2 catalyzes fusion between 
viral and cellular membranes. 
Viral particles attach to host cells through interactions with a variety of cell-surface molecules   
[4–6], and are then internalized and delivered to late endosomes [7–9]. Here, endosomal cysteine 
proteases cleave GP1 to remove heavily glycosylated C–terminal sequences, generating an entry 
intermediate comprising an N–terminal GP1 fragment and GP2 [10–13]. We recently showed that 
cleaved GP must bind to Niemann-Pick C1 (NPC1), a 13-pass transmembrane protein resident in late 
endosomes and implicated in lysosomal cholesterol transport [14]. Events in entry downstream of GP-
NPC1 binding remain obscure, but they must culminate in the GP2-mediated fusion of viral and 
cellular membranes and cytoplasmic delivery of the viral nucleocapsid. The GP conformational 
changes that drive membrane merger are triggered by an undefined host stimulus   
[15–17]. 
The authors of this manuscript [18] and other researchers [19] recently established that NPC1 is an 
essential host factor for filovirus entry, infection, and pathogenesis, and a critical viral receptor [14]. 
NPC1 is a ubiquitous housekeeping protein that plays a crucial role in the regulated efflux of 
cholesterol from lysosomes [20–22], and its loss in humans causes Niemann-Pick type C disease, a 
fatal lysosomal storage disorder [23]. This cellular function of NPC1 is dispensable for filovirus entry 
[14,18,19], which instead requires the direct association of cleaved GP with the second major luminal 
domain of NPC1, domain C [14]. Moreover, synthetic membrane proteins containing NPC1 domain C 
possess viral receptor activity, indicating that it is sufficient for filovirus entry [14]. These findings 
notwithstanding, the greatly reduced levels of viral infection obtained with minimal domain   Viruses 2012, 4                                       
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C-containing receptors and other NPC1 deletion mutants, relative to the WT protein,  suggest 
supporting roles for additional NPC1 sequences in filovirus entry [14]. 
Davies and co-workers [24] identified a protein in vertebrates with substantial homology   
(~40% amino acid sequence identity) to NPC1. This protein, NPC1-like1 (NPC1L1), closely resembles 
NPC1 in overall architecture, possessing 13 transmembrane proteins and three large luminal domains 
(A, C, and I) [24,25]. Moreover, NPC1L1, like NPC1, participates in cellular cholesterol metabolism 
(reviewed in [26]). Unlike NPC1, however, NPC1L1 is expressed only in gut epithelial cells (in all 
mammals examined) and liver hepatocytes (in humans and non-human primates). The two proteins 
also exhibit functional differences: NPC1 is involved in cholesterol efflux from lysosomes, but 
NPC1L1 mediates cholesterol absorption from the extracellular compartment. Here, we show that 
NPC1L1, recently implicated in cell entry by hepatitis C virus [27], completely lacks filovirus receptor 
activity. We exploit this observation, together with the structural similarity between these two proteins, 
to generate a panel of chimeras between NPC1 and NPC1L1. Analysis of this panel for viral receptor 
activity yielded both gain-of-function and loss-of-function phenotypes, allowing the identification of 
sequences in NPC1 that play roles in filovirus entry, and providing an explanation for the failure of 
NPC1L1 to serve as a filovirus receptor. 
 
2. Results and Discussion 
2.1. Human NPC1-like1 (NPC1L1) cannot mediate filovirus entry 
To determine if NPC1L1 can mediate filovirus entry, we used an NPC1-mutant cell line described 
by Chang and co-workers (Chinese hamster ovary [CHO] CT43) [21]. The hamster NPC1 gene in 
CT43 cells contains a 116-bp deletion in exon 19 that creates a frameshift and leads to premature 
translational termination after 933 amino acids; however, no truncated NPC1 polypeptide was detected 
in these cells [28](T.Y. Chang, personal communication). Concordantly, our previous [14,18] and 
current (Figs. 1-2) findings indicate that CT43 cells are completely resistant to filovirus entry and 
infection, but become highly susceptible when wild-type NPC1 is ectopically expressed.   
Taken together, these observations confirm that the CT43 line is functionally NPC1-null.  
We stably expressed a Flag epitope-tagged form of NPC1L1 in CT43 cells (Fig. 1a), and assessed 
their capacity to mediate lysosomal cholesterol transport and viral infection (Fig. 1). As we showed 
previously, the parental CT43 cells accumulated lysosomal cholesterol [21] (Fig. 1b) and were 
completely refractory to infection by vesicular stomatitis virus (VSV) pseudotypes bearing filovirus 
glycoproteins (VSV-GP-EBOV/MARV) (not shown). Also as expected, Flag-tagged WT NPC1 
(NPC1-flag) reversed both cholesterol transport and viral infection defects (Fig. 1b-c). In contrast to 
their counterparts containing NPC1-flag, CT43-NPC1L1-flag cells accumulated lysosomal cholesterol 
and remained resistant to rVSV-GP infection (Fig. 1b-c). Therefore, despite its extensive sequence 
similarity to NPC1 and high level of expression in CT43 cells (Fig. 1a), NPC1L1-flag is inactive at 
both cholesterol clearance and filovirus entry (Fig. 1b-c). Viruses 2012, 4                                       
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2.2. NPC1L1 cannot bind to cleaved EBOV GP 
We recently demonstrated that in vitro-cleaved, but not uncleaved EBOV GP could bind directly to 
human NPC1, and that GP-NPC1 interaction is required for filovirus entry [14]. To determine the 
capacity of NPC1L1 to interact with GP, we tested if intact and/or cleaved EBOV GP (GPCL) could 
retrieve NPC1L1-flag from detergent extracts of CT43 cells (Fig. 1d). Briefly, rVSV-GP-EBOV 
particles were solubilized in a nonionic detergent-containing buffer, and the GP protein in these 
extracts was captured by magnetic beads coated with the GP-specific monoclonal antibody KZ52 [28]. 
The GP-decorated beads were then incubated with detergent extracts of CT43 cells containing either 
NPC1-flag or NPC1L1-flag. As observed previously [14], GPCL, but not GP, could retrieve NPC1-flag 
from cell extracts. However, neither protein could capture NPC1L1-flag (Fig. 1d). Therefore, NPC1L1 
possesses little or no capacity to bind to EBOV GP. Taken together with its failure to support viral 
entry (Fig. 1b-c), these findings provide evidence that NPC1L1 is not an entry receptor for filoviruses. Viruses 2012, 4                                       
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Figure 1. Human Niemann-Pick C1-like1 (NPC1L1) lacks filovirus receptor activity. (a) 
NPC1-null Chinese hamster ovary (CHO) CT43 cells were engineered to express human 
NPC1-flag or NPC1L1-flag. Protein expression was detected by immunoblotting with an 
anti-flag antibody. Mr, relative molecular weight in kilodaltons (kDa). (b) Efflux of 
lysosomal cholesterol mediated by NPC1-flag and NPC1L1-flag in CT43 cells was 
determined by filipin staining and fluorescence microscopy. Scale bar, 20 μm. (c) Infection 
of CT43 cells expressing NPC1-flag or NPC1L1-flag by vesicular stomatitis virus (VSV) 
pseudotypes bearing VSV G or filovirus glycoproteins. Asterisks indicate data points at or 
below the limit of detection. (d) Co-immunoprecipitation (co-IP) of NPC1 and NPC1L1 by 
Ebola virus (EBOV) GP. Magnetic beads coated with GP-specific monoclonal antibody 
KZ52 were incubated with detergent extracts containing no virus (None), uncleaved VSV-
GP, or cleaved VSV-GPCL. Control or glycoprotein-decorated beads were mixed with cell 
extracts containing NPC1-flag or NPC1L1-flag. Beads were then retrieved and flag-tagged 
proteins in the immune pellets and supernatants were detected by immunoblotting (IB). 
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2.3.  NPC1’s  domain C renders NPC1L1 highly competent to bind to EBOV GP and mediate   
filovirus entry 
We showed previously that domain C, the second major luminal domain of NPC1, is critical for 
filovirus entry and binds directly to an in vitro-cleaved form of EBOV GP, GPCL  [14].  
However, because synthetic membrane proteins engineered to contain NPC1’s domain C reconstituted 
viral infection only inefficiently in NPC1-null cells (to ~0.01% of WT NPC1), our prior studies did not 
rule out the potential involvement of other NPC1 sequences to filovirus entry. Here, we took an 
alternative approach to assess the contribution of each major luminal domain of NPC1 in the context of 
the full-length protein: we replaced sequences in NPC1L1 with their counterparts from NPC1, and 
examined the capacity of the resulting chimeras to support viral infection and bind to cleaved EBOV 
GP. NPC1-null CT43 cells were engineered to stably express chimeras containing domains A, C, or I 
from NPC1 in an NPC1L1 background (see Materials and Methods for details). All three chimeras 
(and WT NPC1L1) were found to be expressed at similar levels (Fig. 2c). These cells were then 
challenged with VSV-GP particles bearing glycoproteins from EBOV, Reston virus (RESTV), and 
MARV (Fig. 2a). NPC1L1-NPC1(C), an NPC1L1 chimera bearing NPC1’s domain C, was highly 
competent to mediate filovirus entry. By contrast, NPC1L1 chimeras bearing NPC1’s domains A or I 
were completely inactive, as was an inverse chimera bearing NPC1L1’s domain C in an NPC1 
background (NPC1-NPC1L1(C); Fig. 2a). Importantly, similar results were obtained in infections with 
authentic EBOV and MARV under BSL-4 containment (Fig. 2b). 
We next tested the capacities of the NPCL1-NPC1 chimeras to bind to EBOV GP and GPCL in vitro, 
as described in Fig. 1d. Only the chimera bearing NPC1’s domain C was captured from CT43 
detergent extracts by GPCL (Fig. 2d). Taken together, these findings corroborate our previous work 
identifying domain C as the sole indispensable requirement in NPC1 for GP-NPC1 binding and 
filovirus entry. They also indicate that NPC1L1 cannot act as a filovirus receptor at least in part 
because its divergent domain C cannot recognize and bind to EBOV GP. Viruses 2012, 4                                       
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Figure 2. NPC1’s domain C converts NPC1L1 into a highly effective filovirus receptor.  
(a-b) Infection of CT43 cells expressing NPC1-flag, NPC1L1-flag, or the indicated flag-
tagged NPC1L1-NPC1 chimeras by VSV pseudotypes bearing filovirus glycoproteins (a) 
or authentic filoviruses. nd, not determined. (b). Asterisks indicate data points at or below 
the limit of detection. (c) Expression of NPC1L1-flag and the indicated flag-tagged 
NPC1L1-NPC1 chimeras in CT43 cells was detected by immunoblotting with an anti-flag 
antibody. (d) Co-immunoprecipitation of NPC1L1-NPC1 chimeras by EBOV GP was 
performed as described in Fig. 1d. 
 
2.4. NPC1L1 sequences greatly enhance the capacity of NPC1’s domain C to serve as a filovirus entry 
receptor 
Minimal synthetic membrane proteins containing NPC1’s domain C (NPC1 domain C-TM) are 
competent to mediate filovirus entry, but at greatly reduced levels relative to WT NPC1 [14].   
To evaluate the effect of flanking sequences from NPC1L1 on the viral receptor activity of NPC1 
domain C, we compared the infectivities of VSV particles bearing EBOV or MARV GP in cells 
expressing NPC1 domain C-TM or NPC1L1-NPC1(C) (Fig. 3a-b). We found that insertion of NPC1’s Viruses 2012, 4                                       
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domain C into the divergent NPC1L1 sequence conferred a dramatic (~100-fold) increase in its 
capacity to mediate filovirus entry, with infection by VSV-MARV GP in NPC1L1-NPC1(C)-
expressing cells approaching levels measured in cells expressing WT NPC1 (Fig. 3a). These findings 
suggest two non-mutually exclusive possibilities: first, NPC1L1 sequences provide the structural 
scaffold necessary for optimal folding and/or display of NPC1’s  domain C on the endosomal 
membrane; second, NPC1L1 sequences outside of domain C can substitute for cognate sequences in 
NPC1 in directly mediating filovirus entry, despite the marked evolutionary divergence of NPC1L1 
and NPC1. 
Figure 3.  NPC1L1 sequences greatly enhance the capacity of NPC1’s  domain C to 
mediate filovirus entry. (a) Infection of CT43 cells expressing NPC1-flag, NPC1L1-flag, 
NPC1 domain C fused to NPC1’s transmembrane domain (NPC1 domain C-TM-flag), or 
the chimera NPC1L1-NPC1(C)-flag by VSV pseudotypes bearing filovirus glycoproteins. 
Asterisks indicate data points at or below the limit of detection. (b) Expression of the 
indicated flag-tagged proteins in CT43 cells was detected by immunoblotting with an anti-
flag antibody. Samples in Figs. 3b and 4c were resolved on the same SDS-polyacrylamide 
gel. 
 
2.5. An N–terminal region of NPC1’s domain C can confer filovirus receptor activity upon NPC1L1 
Finally, we reasoned that the sequence (and putative structural) similarities between the C domains 
of NPC1 and NPC1L1 (Fig. 4a), may afford the construction of additional gain-of-function chimeras, 
but this time within domain C itself. Accordingly, we generated two NPC1L1-NPC1 chimeras in 
which an N-terminal or a C-terminal portion of NPC1L1 was replaced with the corresponding 
sequence from NPC1 (NPC1L1-NPC1(373-504)-flag and NPC1L1-NPC1(505-620)-flag, respectively) Viruses 2012, 4                                       
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(Fig. 4b-c). We found that, despite their similar levels of expression in CT43 cells, the two chimeras 
differed dramatically in their capacity to support filovirus entry. NPC1L1 bearing N-terminal domain 
C sequences from NPC1 could mediate viral entry at substantial levels, comparable to that afforded by 
the minimal NPC1 domain C-TM receptor; in contrast, the chimera  bearing C-terminal domain C 
sequences from NPC1 was completely inactive. These findings reveal a critical role for N-terminal 
sequences within domain C in NPC1’s filovirus receptor function. Moreover, given the failure of 
NPC1L1’s domain C to bind to EBOV GP and support infection (Fig. 1), our observations with this 
gain-of-function mutant indicate that N-terminal domain C sequences in NPC1 are directly involved in 
filovirus entry, possibly at the level of GP binding. 
Figure 4. N-terminal sequences from NPC1 domain C render NPC1L1 competent to mediate 
filovirus entry. (a) Alignment of domain C amino acid sequences from human NPC1 and 
NPC1L1. Sequence differences are shaded in gray. Sequences exchanged between domains are 
outlined in red and green. Cysteines  are highlighted in yellow. (b) Infection of CT43 cells 
expressing NPC1L1-flag, NPC1L1-NPC1(C)-flag, or NPC1L1-NPC1 intra-domain C chimeras 
by VSV pseudotypes bearing filovirus glycoproteins. Asterisks indicate data points at or below 
the limit of detection. (c) Expression of the indicated flag-tagged proteins in CT43 cells was 
detected by immunoblotting with an anti-flag antibody. Samples in Figs. 3b and 4c were resolved 
on the same SDS-polyacrylamide gel. 
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3. Experimental Section 
3.1. Cell culture 
NPC1-null (CT43) Chinese hamster ovary (CHO) fibroblasts were maintained in DMEM-Ham’s  
F-12 medium (50-50 mix) supplemented with 10% FCS, L-glutamine, and penicillin–streptomycin. 
Vero African grivet monkey kidney cells and 293T human embryonic kidney cells were maintained in 
DMEM supplemented with 10% FCS, L-glutamine, and penicillin–streptomycin. All mammalian cell 
lines were maintained in a humidified 5% CO2 incubator. 
3.2. NPC1 and NPC1L1 constructs 
Flag-tagged NPC1L1-NPC1 chimeras were constructed by splice overlap extension PCR [29] and 
subcloned into the BamHI  and  SalI  restriction sites of the pBABE-puro retroviral vector [30]. 
NPC1L1-NPC1(A) contains amino acid residues NPC1 residues 1-266 and NPC1L1 residues   
288-1332; NPC1L1-NPC1(C) contains NPC1L1 residues 1-369, NPC1 residues 367-620, and NPC1L1 
residues 633-1332; NPC1L1-NPC1(I) contains NPC1L1 residues 1-868, NPC1 residues 859-1097, and 
NPC1L1 residues 1113-1332. All constructs were verified by automated DNA sequencing. 
CT43 cell populations stably expressing human NPC1-flag, NPC1L1-flag, and NPC1L1-NPC1 
chimeras were generated by retroviral transduction as described previously [14]. 
3.3. Viruses and infections 
VSV pseudotypes  bearing glycoproteins derived from VSV, EBOV, RESTV, and MARV were 
generated as described previously [31]. The authentic filoviruses EBOV-Zaire 1995 and MARV-Ci67 
used in this study have been described previously [32,33]. VSV particles containing GPCL  were 
generated by incubating rVSV-GP-EBOV with thermolysin (200 μg/mL) for 1 h at 37˚C. The protease 
was inactivated by addition of phosphoramidon (1 mM), and reaction mixtures were used immediately. 
Infectivities of VSV pseudotypes were measured by manual counting of eGFP-positive cells using 
fluorescence microscopy at 16-24 h post-infection. 
Cells were exposed to authentic viruses at an MOI of 3 for 1 h. Viral inoculum was then removed 
and fresh culture media was added. At 48 h post-infection, cells were fixed with formalin, and blocked 
with 1% bovine serum albumin. Detection and quantitation of infected cells and uninfected controls 
was done as described previously [14]. 
3.4. NPC1/NPC1L1-containing cell extracts for GP-binding assays 
Extracts were prepared as described previously [14]. CT43 cells expressing NPC1-flag, NPC1L1-
flag, and NPC1L1-NPC1 chimeras were washed with PBS, and packed cell pellets were lysed by 
incubation at 4˚C with NTE-CHAPS buffer (10 mM Tris[pH 7.5], 140 mM NaCl, 1 mM EDTA, 0.5% 
vol/vol 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate)) supplemented with a protease 
inhibitor cocktail (Roche). Typically, 1 mL buffer was used to lyse 2×10
7 cell-equivalents. To promote 
cell lysis, cell suspensions were probe-sonicated (lowest setting, 5 pulses of 5 sec each) in an ice-water Viruses 2012, 4                                       
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bath. Lysates were cleared by centrifugation at 14,000 ×g for 10 min, and supernatants were used 
immediately. 
3.5. GP-NPC1 co-immunoprecipitation (co-IP) assays 
Co-IP assays were carried out as described previously [14]. Protein G-coated magnetic beads (20 
μL/reaction; Spherotech) were incubated with the GP-specific monoclonal antibody KZ52 (5 μg) [28] 
for 1 h, washed to remove unbound antibody, and then added to uncleaved or in vitro-cleaved VSV-
GP-EBOV particles (5 μL concentrated virus; 10
7–10
8 infectious units) in NTE-CHAPS buffer. Bead-
virus mixtures were incubated for 2 h at room temperature, and then added to crude detergent extracts 
of CHO CT43 cells expressing flag-tagged NPC1 or related proteins (2×10
6 cell-equivalents). After 
overnight incubation with mixing at 4˚C, beads were retrieved with a magnet, extensively washed with 
NTE-CHAPS, and heated in Laemmli sample buffer to elute bound proteins. Solubilized proteins were 
subjected to SDS-polyacrylamide gel electrophoresis, and flag-tagged proteins were detected by 
immunoblotting with an anti-flag antibody (Sigma Aldrich). Typically 50-100% of each pellet sample 
and 5-10% of each supernatant were loaded on gels. 
4. Conclusions 
Our findings afford the following conclusions: (1) They firmly establish that NPC1, but not its 
structurally- and functionally-related paralog NPC1L1, can serve as a filovirus receptor by binding 
directly to the viral glycoprotein. (2) They confirm the indispensable role of domain C, NPC1’s second 
major luminal domain, for filovirus receptor activity. (3) They reveal that NPC1L1 is inactive as a 
filovirus receptor because its divergent domain C cannot bind to the viral glycoprotein.   
(4) Non-domain C sequences derived from NPC1L1 substitute essentially fully for their counterparts 
from NPC1, arguing that structural and/or functional elements conserved among NPC1 gene family 
members play key roles in mediating filovirus entry. Additional studies to identify these conserved 
sequences in NPC1 and NPC1L1 and define their roles in filovirus entry are therefore warranted.   
(5) An 131-amino acid sequence approximating the N-terminal half of NPC1 domain C confers 
filovirus  receptor activity on NPC1L1, suggesting that amino acid residues within this sequence 
directly contact GP during filovirus entry. Our current work is aimed at further delineating sequences 
in domain C that play direct roles in NPC1’s filovirus receptor function. 
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